Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
May 4, 2013
DVS SCIENCES INTRODUCES THE CYTOF® 2 MASS CYTOMETER AND NEW MAXPAR® PANEL KITS FOR TRANSFORMATIONAL HIGH-PARAMETER SINGLE CELL ANALYSIS
May 3, 2013
AMBRX INITIATES COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR DISCOVERY, DEVELOPMENT OF NEXT-GENERATION ANTIBODY DRUG CONJUGATES
May 3, 2013
BMS PARTNERS AGAIN WITH AMBRX, IN UP-TO-$112M-AND-UP ADC COLLABORATION
April 24, 2013
ACHAOGEN AWARDED $60M CONTRACT OPTION BY BARDA FOR THE CLINICAL DEVELOPMENT OF PLAZOMICIN
April 9, 2013
IGENICA APPOINTS THI-SAU MIGONE, PH.D., AS CHIEF SCIENTIFIC OFFICER
April 9, 2013
CLEAVE BIOSCIENCES ADDS NEW INVESTOR AND $10 MILLION TO SERIES A FINANCING
April 4, 2013
ASTELLAS AND AMBRX INITIATE COLLABORATION FOR DISCOVERY AND DEVELOPMENT OF NEXT GENERATION ANTIBODY DRUG CONJUGATES FOR ONCOLOGY
March 25, 2013
NOVIRA THERAPEUTICS COMPLETES $25 MILLION SERIES A FINANCING
February 28, 2013
BIOTIE: SELINCRO (NALMEFENE) RECEIVES EUROPEAN MARKETING AUTHORIZATION
February 26, 2013
UCB TO LICENSE WORLDWIDE RIGHTS TO TOZADENANT IN PARKINSON’S DISEASE FROM BIOTIE
« Previous Page
1
…
103
104
105
106
107
…
118
Next Page »